JP2007511539A5 - - Google Patents

Download PDF

Info

Publication number
JP2007511539A5
JP2007511539A5 JP2006540034A JP2006540034A JP2007511539A5 JP 2007511539 A5 JP2007511539 A5 JP 2007511539A5 JP 2006540034 A JP2006540034 A JP 2006540034A JP 2006540034 A JP2006540034 A JP 2006540034A JP 2007511539 A5 JP2007511539 A5 JP 2007511539A5
Authority
JP
Japan
Prior art keywords
aat
composition
concentration
pharmaceutical composition
antioxidant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006540034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007511539A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/038650 external-priority patent/WO2005048985A2/en
Publication of JP2007511539A publication Critical patent/JP2007511539A/ja
Publication of JP2007511539A5 publication Critical patent/JP2007511539A5/ja
Pending legal-status Critical Current

Links

JP2006540034A 2003-11-14 2004-11-11 α１−抗トリプシン組成物およびこのような組成物を用いた処置方法 Pending JP2007511539A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52054903P 2003-11-14 2003-11-14
PCT/US2004/038650 WO2005048985A2 (en) 2003-11-14 2004-11-11 Alpha 1-antitrypsin compositions and treatment methods using such compositions

Publications (2)

Publication Number Publication Date
JP2007511539A JP2007511539A (ja) 2007-05-10
JP2007511539A5 true JP2007511539A5 (https=) 2007-12-27

Family

ID=34619481

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006540034A Pending JP2007511539A (ja) 2003-11-14 2004-11-11 α１−抗トリプシン組成物およびこのような組成物を用いた処置方法

Country Status (12)

Country Link
US (2) US20080312136A1 (https=)
EP (1) EP1684719B1 (https=)
JP (1) JP2007511539A (https=)
AT (1) ATE530165T1 (https=)
AU (1) AU2004290587B2 (https=)
CA (1) CA2545855A1 (https=)
DK (1) DK1684719T3 (https=)
ES (1) ES2375706T3 (https=)
PL (1) PL1684719T3 (https=)
PT (1) PT1684719E (https=)
SI (1) SI1684719T1 (https=)
WO (1) WO2005048985A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2559062A1 (en) * 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
ES2399449T3 (es) 2006-02-09 2013-04-01 Kamada Ltd. Administración pulmonar de un inhibidor de proteinasa alfa-1
CN102131827A (zh) * 2007-12-13 2011-07-20 葛兰素集团有限公司 用于肺部传递给药的组合物
TR201809898T4 (tr) 2009-11-03 2018-07-23 Grifols Therapeutics Llc Alfa-1 protei̇naz i̇nhi̇bi̇törüne yöneli̇k bi̇leşi̇m, yöntem ve ki̇t.
PT2503995T (pt) 2009-11-24 2017-11-23 Grifols Therapeutics Inc Métodos de liofilização, composições e kits
US20130034573A1 (en) * 2009-12-22 2013-02-07 Celldex Therapeutics, Inc. Vaccine compositions
CA2844878C (en) * 2011-12-30 2017-11-28 Grifols, S.A. Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations
ES2799153T3 (es) * 2013-03-29 2020-12-15 Univ Colorado Regents Alfa 1 antitripsina para uso en la preparación de un sujeto para trasplante
WO2015191892A2 (en) * 2014-06-11 2015-12-17 Beth Israel Deaconess Medical Center, Inc. α1-ANTITRYPSIN COMPOSITIONS AND METHODS OF TREATING AUTOIMMUNE DISEASES
US20210085764A1 (en) * 2016-12-22 2021-03-25 Kamada Ltd. Dry powder formulations of alpha-1 antitrypsin
CA3054267A1 (en) * 2017-02-21 2018-08-30 Kamada Ltd. Methods and uses of alpha 1-antitrypsin for early intervention in pulmonary diseases
WO2018183705A1 (en) 2017-03-29 2018-10-04 Cornell University Oxidation-resistant aat gene therapy
WO2019087184A1 (en) * 2017-10-31 2019-05-09 Kamada Ltd Methods and compositions for reducing lung injury associated with lung transplantation
IL267923B2 (en) 2018-08-02 2023-06-01 Grifols Worldwide Operations Ltd The composition containing the most concentrated alpha-1 type protein inhibitor and a method for obtaining it
CN113365513B (zh) * 2018-10-23 2025-04-25 G·E·霍格 用于治疗肺的组合物和方法
WO2020163703A1 (en) 2019-02-08 2020-08-13 Krystal Biotech, Inc. Compositions and methods for delivering cftr polypeptides
US20210189427A1 (en) * 2019-12-20 2021-06-24 Krystal Biotech, Inc. Compositions and methods for gene delivery to the airways and/or lungs
GB202102258D0 (en) * 2021-02-17 2021-03-31 Arecor Ltd Novel composition

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4150071A (en) * 1977-08-26 1979-04-17 Respiratory Care, Inc. Nebulizer
IT1105653B (it) * 1978-06-20 1985-11-04 Craighero Margherita Apparecchio aerosolizzatore
US4253468A (en) * 1978-08-14 1981-03-03 Steven Lehmbeck Nebulizer attachment
US4198969A (en) * 1978-10-06 1980-04-22 Baxter Travenol Laboratories, Inc. Suction-operated nebulizer
US4453542A (en) * 1980-12-08 1984-06-12 Vortran Corporation Vortex-generating medical products
US4775622A (en) * 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US5218091A (en) * 1982-08-13 1993-06-08 Zymogenetics, Inc. Glycolytic promoters for regulated protein expression: protease inhibitor
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US5010003A (en) * 1983-04-25 1991-04-23 Genentech, Inc. Use of yeast homologous signals to secrete heterologous proteins
WO1985002346A1 (en) * 1983-11-28 1985-06-06 Vortran Corporation Gas-powered nebulizer
US4711848A (en) * 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
US4940661A (en) * 1984-05-17 1990-07-10 Genentech, Inc. Metallothionein transcription control sequences and use thereof
US4931373A (en) * 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4732973A (en) * 1984-06-14 1988-03-22 Chiron Corporation Active site modified protease α-1-antitrypsin inhibitors
US4752576A (en) * 1984-06-14 1988-06-21 Chiron Corporation Expression of α-1 antitrypsin in yeast
US4837148A (en) * 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US5013652A (en) * 1986-10-14 1991-05-07 Genex Corporation Composite yeast vectors
US5114917A (en) * 1986-12-24 1992-05-19 John Lezdey Treatment of inflammation using alpha 1-antichymotrypsin
US5166134A (en) * 1986-12-24 1992-11-24 John Lezdey Treatment of allergic rhinitis
US4839283A (en) * 1986-12-30 1989-06-13 Zymogenetics, Inc. Method of expressing alpha-1-antitrypsin in yeast
JP2656944B2 (ja) * 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化
US4929555A (en) * 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US6068994A (en) * 1989-08-07 2000-05-30 Chiron Corporation Ubiquitin expression system
FR2660509B1 (fr) * 1990-03-29 1993-11-19 Alcatel Cit Etage differentiel de sortie d'equipement electronique.
US5012652A (en) * 1990-09-21 1991-05-07 Carrier Corporation Crankcase heater control for hermetic refrigerant compressors
US5134119A (en) * 1990-10-16 1992-07-28 Lezdey John Treatment of inflammation using 358 substituted alpha-antitrypsin
US5268384A (en) * 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
US5114953A (en) * 1990-11-21 1992-05-19 University Of Florida Treatment for tissue ulceration
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
US5256657A (en) * 1991-08-19 1993-10-26 Sterling Winthrop, Inc. Succinamide derivative matrix-metalloprotease inhibitors
TW282490B (https=) * 1992-12-15 1996-08-01 Ciba Geigy Ag
US5594106A (en) * 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
JP3779728B2 (ja) * 1994-08-05 2006-05-31 カイロン コーポレイション 組織因子活性インヒビターの産生
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5780440A (en) * 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
US6610683B2 (en) * 1996-09-12 2003-08-26 Idun Pharmaceuticals, Inc. Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
EP1659173A1 (en) * 1997-10-01 2006-05-24 DSMIP Assets B.V. Protein production process
US20010006939A1 (en) * 1997-10-03 2001-07-05 Ralph W. Niven Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
WO1999032135A1 (en) * 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
WO1999032150A1 (en) * 1997-12-23 1999-07-01 Warner-Lambert Company Ace inhibitor-mmp inhibitor combinations
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
WO2000051623A2 (en) * 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
EE200200426A (et) * 2000-01-31 2003-12-15 Pfizer Products Inc. PDE4 isosüümide inhibiitoritena kasulikud pürimidiinkarboksamiidid
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US6991824B2 (en) * 2000-05-02 2006-01-31 Ventria Bioscience Expression of human milk proteins in transgenic plants
US20020099013A1 (en) * 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US7247704B2 (en) * 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
PA8539301A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
US6544497B2 (en) * 2001-02-15 2003-04-08 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
JP2003024076A (ja) * 2001-07-12 2003-01-28 Kirin Brewery Co Ltd Ｔｐｏ変異体タンパク質
FR2832569B1 (fr) * 2001-11-22 2007-04-27 Evolium Sas Procede de transmission de communications dans un systeme de telecommunication de type cellulaire utilisant des bandes de frequences porteuses adjacentes
US20030211548A1 (en) * 2002-01-29 2003-11-13 Oncolmmunin, Inc. Visualization and quantitiation of cellular cytotoxicity using cell-permeable fluorogenic protease substrates and caspase activity indicator markers
CA2545458A1 (en) * 2003-11-10 2005-05-26 Arriva-Prometic Inc. Dry recombinant human alpha 1-antitrypsin formulation

Similar Documents

Publication Publication Date Title
JP2007511539A5 (https=)
ES2664624T3 (es) Alfa-I antitripsina para tratar episodios de exacerbación de enfermedades pulmonares
CA1327309C (en) Aerosolization of protein therapeutic agent
JP4338214B2 (ja) エリトロポエチンの肺投与
JP2024170583A5 (https=)
US20020127188A1 (en) Composition for pulmonary administration comprising a drug and a hydrophobic amino acid
AU2017298202A1 (en) Methods for treating cystic fibrosis and other diseases affecting mucosal surfaces
Jin et al. Pulmonary delivery of the Kv1. 3-blocking peptide HsTX1 [R14A] for the treatment of autoimmune diseases
US11559498B2 (en) Compositions and methods for in vivo lung and blood SNO repletion
Ozer Alternative applications for drug delivery: Nasal and pulmonary routes
CN105832715A (zh) 炎症调节剂用于治疗囊性纤维化和其他肺部疾病中的感染的用途
ES2928050T3 (es) Peptidomimético de horquilla beta con actividad inhibidora de elastasa y formas de dosificación en aerosol del mismo
JP2007528409A (ja) プロテアーゼインヒビターの低用量吸入による慢性閉塞性肺疾患の処置
ES2791775B2 (es) Formulaciones de epinefrina intranasal y metodos para el tratamiento de enfermedades
CN116234563A (zh) 抗致病治疗方法
JP2009521473A5 (https=)
JP2007511539A (ja) α１−抗トリプシン組成物およびこのような組成物を用いた処置方法
KR20220137051A (ko) 염증성 폐질환의 흡입치료용 5-아미노-2,3-디히드로-1,4-프탈라진디온
IT202000005026A1 (it) Lattoferrina per uso inalatorio ad azione antivirale
US20070049641A1 (en) Methods for treating and monitoring inflammation and redox imbalance cystic fibrosis
CN103841958A (zh) 组合物
Kwok et al. Pulmonary delivery of peptides and proteins
CN102348465A (zh) 慢性阻塞性肺疾病改善剂
US20240009227A1 (en) Use of a heparin composition in the treatment of viral lung diseases, acute and/or chronic lung diseases by soft mist inhaler or vibration mesh technology nebulizer through inhalation route
CN105764488A (zh) 用于向受试者的气道施用酶的组合物和方法